Literature DB >> 18379363

Variation in experts' beliefs about lung cancer growth, progression, and prognosis.

Ellen M Schultz1, Gerard A Silvestri, Michael K Gould.   

Abstract

INTRODUCTION: Little is known about the natural history of malignant solitary pulmonary nodules (SPN). Experts' beliefs may help fill these knowledge gaps and explain variation in clinical practices.
METHODS: Using a modified Delphi process, we surveyed a group of lung cancer experts about tumor growth, disease progression, and prognosis in patients with malignant SPN. After completing the first survey, experts were given the opportunity during a second survey to revise their responses in light of their peers' beliefs.
RESULTS: The response rate was 100% (14 of 14) for both surveys. There was consensus that disease progression depends on the tumor growth rate, that survival for patients with untreated lung cancer is approximated by a declining exponential function, and that treatment is delayed by approximately 1 tumor volume doubling time (TVDT) in patients who undergo a period of "watchful waiting." Just over half of experts (8 of 14) agreed that lung cancer progresses in three steps (from local to regional to distant disease), whereas 43% (6 of 14) preferred a 2-step model (from local to systemic disease). Likewise, 64% of experts (9 of 14) believed that malignant nodules grow exponentially, whereas 36% (5 of 14) believed that growth is slower than exponential. Experts' estimates of the risk of disease progression during a period of observation lasting 1 TVDT varied from 1 to 50%. Estimates of 5-year survival for patients in whom diagnosis and treatment were delayed by 1 TVDT varied between 40% and 80%.
CONCLUSIONS: There is substantial variability in experts' beliefs about the natural history of untreated, malignant SPN. Different beliefs may be partly responsible for variation in management practices.

Entities:  

Mesh:

Year:  2008        PMID: 18379363      PMCID: PMC2903546          DOI: 10.1097/JTO.0b013e318167146b

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  7 in total

1.  Differentiation of benign and malignant pulmonary nodules by growth rate.

Authors:  M H NATHAN; V P COLLINS; R A ADAMS
Journal:  Radiology       Date:  1962-08       Impact factor: 11.105

Review 2.  Consensus methods for medical and health services research.

Authors:  J Jones; D Hunter
Journal:  BMJ       Date:  1995-08-05

Review 3.  Consensus development methods, and their use in clinical guideline development.

Authors:  M K Murphy; N A Black; D L Lamping; C M McKee; C F Sanderson; J Askham; T Marteau
Journal:  Health Technol Assess       Date:  1998       Impact factor: 4.014

4.  The natural history of lung cancer: a review based on rates of tumour growth.

Authors:  D M Geddes
Journal:  Br J Dis Chest       Date:  1979-01

Review 5.  Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement.

Authors:  M H Baumann; C Strange; J E Heffner; R Light; T J Kirby; J Klein; J D Luketich; E A Panacek; S A Sahn
Journal:  Chest       Date:  2001-02       Impact factor: 9.410

6.  Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition).

Authors:  Michael K Gould; James Fletcher; Mark D Iannettoni; William R Lynch; David E Midthun; David P Naidich; David E Ost
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

7.  Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules.

Authors:  Michael K Gould; Gillian D Sanders; Paul G Barnett; Chara E Rydzak; Courtney C Maclean; Mark B McClellan; Douglas K Owens
Journal:  Ann Intern Med       Date:  2003-05-06       Impact factor: 25.391

  7 in total
  7 in total

1.  Retrospective assessment of interobserver agreement and accuracy in classifications and measurements in subsolid nodules with solid components less than 8mm: which window setting is better?

Authors:  Roh-Eul Yoo; Jin Mo Goo; Eui Jin Hwang; Soon Ho Yoon; Chang Hyun Lee; Chang Min Park; Soyeon Ahn
Journal:  Eur Radiol       Date:  2016-07-25       Impact factor: 5.315

2.  Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model.

Authors:  Ray S Lin; Sylvia K Plevritis
Journal:  Cancer Causes Control       Date:  2011-11-25       Impact factor: 2.506

Review 3.  Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer.

Authors:  Tim N Beck; Adaeze J Chikwem; Nehal R Solanki; Erica A Golemis
Journal:  Physiol Genomics       Date:  2014-08-05       Impact factor: 3.107

4.  Is expert opinion reliable when estimating transition probabilities? The case of HCV-related cirrhosis in Egypt.

Authors:  Anthony Cousien; Dorothée Obach; Sylvie Deuffic-Burban; Aya Mostafa; Gamal Esmat; Valérie Canva; Mohamed El Kassas; Mohammad El-Sayed; Wagida A Anwar; Arnaud Fontanet; Mostafa K Mohamed; Yazdan Yazdanpanah
Journal:  BMC Med Res Methodol       Date:  2014-03-17       Impact factor: 4.615

5.  Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules.

Authors:  John Edelsberg; Derek Weycker; Mark Atwood; Geoffrey Hamilton-Fairley; James R Jett
Journal:  PLoS One       Date:  2018-05-22       Impact factor: 3.240

6.  Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.

Authors:  Gerard A Silvestri; Nichole T Tanner; Paul Kearney; Anil Vachani; Pierre P Massion; Alexander Porter; Steven C Springmeyer; Kenneth C Fang; David Midthun; Peter J Mazzone
Journal:  Chest       Date:  2018-03-01       Impact factor: 9.410

7.  Solitary pulmonary nodule: A diagnostic algorithm in the light of current imaging technique.

Authors:  Ali Nawaz Khan; Hamdan H Al-Jahdali; Klaus L Irion; Mohammad Arabi; Shyam Sunder Koteyar
Journal:  Avicenna J Med       Date:  2011-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.